Study guide

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal

Key Takeaways Explain This Topic AI

SSRIs are first-line for depression and anxiety disorders; they take 2 to 6 weeks to work and can cause hyponatremia, sexual dysfunction and a suicidality warning in young people.

Tricyclic overdose causes coma, seizures, anticholinergic signs and a wide QRS (over 100 ms) with a tall terminal R in aVR, treated with IV sodium bicarbonate.

Serotonin syndrome causes clonus and hyperreflexia with hyperthermia after combining serotonergic drugs, and is treated with withdrawal of the drugs, benzodiazepines and cyproheptadine; neuroleptic malignant syndrome causes lead-pipe rigidity and high CK.

Lithium (target level 0.6 to 1.2 mEq/L) is raised to toxic levels by thiazides, NSAIDs, ACE inhibitors and dehydration, and causes hypothyroidism and nephrogenic diabetes insipidus.

Clozapine is reserved for treatment-resistant schizophrenia and requires regular absolute neutrophil count monitoring for agranulocytosis.

Last updated: October 2026

Why this area matters

The TOS covers drug treatment of:

  • psychosis and schizophrenia;
  • bipolar disorder;
  • depression;
  • anxiety;
  • sleep disorders ;

psychiatric emergencies .

Psychotropic drugs have narrow margins (lithium, tricyclics), dangerous interactions (serotonergic combinations, MAO inhibitors) and serious idiosyncratic reactions (NMS, agranulocytosis). Overdose of psychiatric drugs is a common poisoning.

  • Antidepressant Pharmacology & Serotonergic Crises
  • Major Antidepressant Classes

Selective Serotonin Reuptake Inhibitors (SSRIs: Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram) :

Mechanism : Selectively block the presynaptic serotonin reuptake transporter (SERT), prolonging serotonin action in the synaptic cleft. First-line therapy for Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Panic Disorder, OCD, and PTSD.

Adverse Effects : Sexual dysfunction ( 30 – 50 % 30\text{--}50\% 30 – 50% : decreased libido, erectile failure, anorgasmia), gastrointestinal distress (nausea, diarrhea), insomnia, syndrome of inappropriate antidiuretic hormone secretion (SIADH) causing hyponatremia in the elderly, and an FDA boxed warning for increased suicidal ideation in children, adolescents, and young adults under 25 years. Paroxetine carries cardiac teratogenicity risks (ventricular septal defects).

Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs: Venlafaxine, Duloxetine, Desvenlafaxine) :

Mechanism : Inhibit both SERT and the norepinephrine transporter (NET). Useful in comorbid depression with chronic neuropathic pain (diabetic peripheral neuropathy, fibromyalgia). Adverse effects include dose-dependent diastolic hypertension (noradrenergic peripheral vasoconstriction), diaphoresis, and tachycardia.

Tricyclic Antidepressants (TCAs: Amitriptyline, Nortriptyline, Imipramine, Clomipramine) :

Mechanism : Inhibit SERT and NET; simultaneously block muscarinic M 1 M_1 M 1 ​ , histaminergic H 1 H_1 H 1 ​ , and alpha-1 adrenergic receptors, as well as myocardial fast voltage-gated sodium channels ( N a v 1.5 Nav1.5 N a v 1.5 ).

Overdose Presentation — "The 3 Cs" :

Convulsions : Seizures mediated by central GABA-A antagonism.

Coma : Profound CNS sedation mediated by H 1 H_1 H 1 ​ and central anticholinergic blockade.

Cardiotoxicity : Fast sodium channel blockade slows Phase 0 ventricular depolarization, manifesting on ECG as QRS prolongation ( > 100 ms > 100\text{ ms} > 100 ms ) , rightward terminal 40-ms axis shift (prominent R wave in lead aVR > 3 mm > 3\text{ mm} > 3 mm ), PR and QT prolongation, and lethal ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation, refractory hypotension).

Antidote / Treatment : Intravenous Sodium Bicarbonate ( NaHCO 3 \text{NaHCO}_3 NaHCO 3 ​ ) . Boluses administered when QRS duration exceeds 100 ms 100\text{ ms} 100 ms or in the presence of ventricular arrhythmias and hypotension. Mechanism: provides an extracellular sodium load ( N a + Na^+ N a + ) that outcompetes TCA binding to fast sodium channels, while extracellular alkalinization ( pH 7.50 – 7.55 \text{pH } 7.50\text{--}7.55 pH 7.50 – 7.55 ) deprotonates the lipid-soluble amine TCA molecule, reducing its affinity for sodium channel receptor sites.

Monoamine Oxidase Inhibitors (MAOIs: Phenelzine, Tranylcypromine, Isocarboxazid, Selegiline) :

Mechanism : Irreversibly inhibit MAO-A (degrades serotonin, norepinephrine, dopamine) and MAO-B (degrades dopamine).

Tyramine Hypertensive Crisis : Dietary tyramine (found in aged cheeses, red wine, cured meats, draft beer, soy sauce) is normally degraded by intestinal and hepatic MAO-A. Under MAOI inhibition, absorbed tyramine enters systemic circulation, enters presynaptic adrenergic terminals via NET, and displaces vesicular norepinephrine into the synaptic cleft. The massive noradrenergic surge produces acute severe hypertension (BP > 180 / 120 mmHg > 180/120\text{ mmHg} > 180/120 mmHg , throbbing occipital headache, intracranial hemorrhage, acute myocardial infarction). Treated with IV phentolamine or nitroprusside.

Washout Period : When transitioning between an MAOI and another antidepressant, a strict 14-day (2-week) washout period is required to allow resynthesis of MAO enzymes. A 5-week washout is required when switching from fluoxetine to an MAOI due to fluoxetine's exceptionally long half-life and active metabolite (norfluoxetine, t 1 / 2 ≈ 7 – 15 days t_{1/2} \approx 7\text{--}15\text{ days} t 1/2 ​ ≈ 7 – 15 days ).

Serotonin Syndrome

Hyperstimulation of central and peripheral 5- H T 1 A HT_{1A} H T 1 A ​ and 5- H T 2 A HT_{2A} H T 2 A ​ receptors, triggered by combining serotonergic agents (SSRIs, SNRIs, TCAs, MAOIs, Tramadol, Meperidine, Dextromethorphan, Linezolid, MDMA, St. John's wort).

Diagnostic Triad :

Neuromuscular Hyperactivity : Spontaneous or inducible clonus , marked hyperreflexia (lower extremities ≫ \gg ≫ upper), tremor, shivering.

Autonomic Instability : Hyperthermia, diaphoresis, tachycardia, labile blood pressure, mydriasis, hyperactive bowel sounds with diarrhea.

Altered Mental Status : Agitation, delirium, confusion.

Management : Discontinue all serotonergic agents immediately; aggressive cooling and IV fluids; benzodiazepines for agitation; specific antidote is Cyproheptadine (a first-generation antihistamine with potent 5- H T 2 HT_2 H T 2 ​ receptor antagonist activity).

Anxiolytics, Hypnotics & Antidotes: Benzodiazepines vs. Barbiturates

Both drug classes bind the pentameric GABA A \text{GABA}_A GABA A ​ receptor-chloride channel complex, but via distinct allosteric binding sites and kinetic mechanisms.

Property Benzodiazepines (Diazepam, Lorazepam, Midazolam, Alprazolam) Barbiturates (Phenobarbital, Pentobarbital, Thiopental)

Receptor Mechanism Bind α – γ \alpha\text{--}\gamma α – γ subunit interface; increase FREQUENCY of channel opening in response to GABA Bind distinct allosteric site; increase DURATION of channel opening ; directly open C l − Cl^- C l − channels at high doses

Therapeutic Index High therapeutic index ; ceiling effect on respiratory depression when taken alone Low therapeutic index ; severe fatal respiratory depression and coma in overdose

Hepatic Interactions Minimal CYP450 induction; LOT agents (Lorazepam, Oxazepam, Temazepam) undergo direct Phase II glucuronidation Potent CYP450 inducers ; accelerate metabolism of warfarin, oral contraceptives, steroids

Overdose Presentation Somnolence, dysarthria, ataxia, normal vital signs and pupils (unless combined with alcohol or opioids) Profound coma, small or normal pupils, respiratory arrest, severe hypotension, hypothermia

Specific Antidote Flumazenil (competitive antagonist at BZD binding site on GABA A \text{GABA}_A GABA A ​ ) None; supportive care, urinary alkalinization with sodium bicarbonate for phenobarbital

PLE High-Yield Point (Flumazenil Danger) : Routine administration of flumazenil in comatose overdose patients is dangerous. In patients with chronic benzodiazepine dependence or co-ingestion of proconvulsant drugs (especially TCAs), flumazenil precipitates refractory, life-threatening withdrawal seizures that cannot be stopped with benzodiazepines because their receptors are blocked.

  • Antipsychotic Pharmacology: Extrapyramidal Symptoms vs. Metabolic Syndrome
  • Typical / First-Generation Antipsychotics (FGAs: Haloperidol, Fluphenazine, Chlorpromazine)

Mechanism : High-potency antagonism of dopamine D 2 D_2 D 2 ​ receptors in the mesolimbic pathway (reduces positive symptoms of schizophrenia). Simultaneous blockade of nigrostriatal D 2 D_2 D 2 ​ receptors produces high rates of Extrapyramidal Symptoms (EPS) :

Acute Dystonia (hours to 5 days): Sudden, painful spasms of neck muscles (torticollis), ocular muscles (oculogyric crisis), tongue protrusion, or laryngospasm. Treatment: IV or IM anticholinergic ( Diphenhydramine or Benztropine ).

Akathisia (days to weeks): Subjective, distressing motor restlessness and inability to sit still. Treatment: Beta-blockers ( Propranolol ), benzodiazepines, or dosage reduction.

Parkinsonism (weeks to months): Bradykinesia, cogwheel rigidity, resting pill-rolling tremor, masked facies. Treatment: Anticholinergics (Benztropine) or dopamine agonists that do not worsen psychosis ( Amantadine ; avoid levodopa).

Tardive Dyskinesia (months to years): Involuntary choreoathetoid movements of face, mouth, tongue (lip smacking, tongue darting), and limbs due to chronic dopamine receptor upregulation and supersensitivity. Often irreversible. Anticholinergics worsen tardive dyskinesia. Treatment: Switch to an atypical antipsychotic with low D 2 D_2 D 2 ​ affinity ( Clozapine or Quetiapine ); vesicular monoamine transporter 2 (VMAT2) inhibitors ( Valbenazine , Deutetrabenazine ).

Neuroleptic Malignant Syndrome (NMS) : Life-threatening hyperpyrexic reaction to dopamine blockade. Mnemonic FALTER : F ever (severe hyperthermia > 40 ∘ C > 40^\circ\text{C} > 4 0 ∘ C ), A utonomic instability (tachycardia, diaphoresis, labile BP), L eukocytosis, T remor, E levated creatine kinase (CK, from rhabdomyolysis), R igidity ("lead-pipe" generalized rigidity). Distinguished from Serotonin Syndrome by lead-pipe rigidity and hyporeflexia (versus clonus/hyperreflexia). Treatment: Stop antipsychotic; intensive ICU cooling and hydration; pharmacotherapy with Dantrolene (ryanodine receptor blocker) and Bromocriptine (dopamine agonist).

Atypical / Second-Generation Antipsychotics (SGAs: Olanzapine, Quetiapine, Risperidone, Clozapine, Aripiprazole)

Mechanism : Dual antagonists of 5- H T 2 A HT_{2A} H T 2 A ​ and D 2 D_2 D 2 ​ receptors (Aripiprazole is a partial D 2 D_2 D 2 ​ agonist). Lower risk of EPS, but carry high risk of Metabolic Syndrome (weight gain, dyslipidemia, hyperglycemia, new-onset diabetes; highest risk with Olanzapine and Clozapine ; lowest with Aripiprazole and Ziprasidone).

Risperidone : High affinity for D 2 D_2 D 2 ​ ; causes highest incidence of Hyperprolactinemia (galactorrhea, amenorrhea, gynecomastia, sexual dysfunction).

Clozapine :

Uniquely effective for treatment-resistant schizophrenia (failure of ≥ 2 \ge 2 ≥ 2 prior antipsychotic trials) and for reducing suicidal behavior in schizophrenia.

Major Adverse Effects :

Agranulocytosis ( 1 – 2 % 1\text{--}2\% 1 – 2% risk): Potentially fatal bone marrow suppression. Requires mandatory baseline and frequent serial monitoring of the Absolute Neutrophil Count (ANC) . Clozapine must be withheld if ANC drops < 1 , 000 / μ L < 1,000/\mu\text{L} < 1 , 000/ μ L ( < 1.0 × 10 9 / L < 1.0 \times 10^9/\text{L} < 1.0 × 1 0 9 / L ) or permanently discontinued if < 500 / μ L < 500/\mu\text{L} < 500/ μ L .

Myocarditis and cardiomyopathy (monitor troponin and CRP).

Dose-dependent seizure risk (lowers seizure threshold).

Severe gastrointestinal hypomotility (paralytic ileus).

  • Mood Stabilizers & Antiepileptic Therapeutics
  • Lithium Pharmacology & Toxicity

Mechanism : Inhibits inositol monophosphatase (depleting cellular inositol and dampening I P 3 / D A G IP_3/DAG I P 3 ​ / D A G signaling) and inhibits glycogen synthase kinase-3 (GSK-3). First-line mood stabilizer for acute mania and maintenance in Bipolar I Disorder; proven to reduce suicide risk.

Renal Clearance Dynamics : Excreted almost entirely unchanged by the kidneys; handled identically to sodium in the renal proximal tubule. Any physiological state or medication that depletes sodium or decreases GFR causes compensatory increased proximal tubular lithium reabsorption, precipitating acute lithium toxicity . Classic precipitating drugs: Thiazide diuretics (highest risk), NSAIDs (reduce renal prostaglandin synthesis and GFR), and ACE inhibitors / ARBs .

Narrow Therapeutic Window : 0.6 – 1.2 mEq/L 0.6\text{--}1.2\text{ mEq/L} 0.6 – 1.2 mEq/L . Acute toxicity ( > 1.5 mEq/L > 1.5\text{ mEq/L} > 1.5 mEq/L ) manifests with coarse tremors, ataxia, slurred speech, confusion, and vomiting; levels > 2.5 mEq/L > 2.5\text{ mEq/L} > 2.5 mEq/L cause seizures, coma, arrhythmias, and permanent neurological injury. Severe toxicity is managed with emergency hemodialysis .

Chronic Adverse Effects :

Nephrogenic Diabetes Insipidus (NDI) : Lithium enters collecting duct principal cells via ENaC channels, uncoupling vasopressin V 2 V_2 V 2 ​ receptor signaling and aquaporin-2 water channel insertion (polyuria, polydipsia; treated with Amiloride to block ENaC entry).

Hypothyroidism & Goiter : Inhibits thyroid hormone synthesis and release (monitor serum TSH).

Teratogenicity : Category D; causes Ebstein Anomaly (apical displacement of tricuspid leaflets with atrialization of the right ventricle).

Bipolar disorder, anxiety and insomnia

Acute mania:

lithium , valproate or an atypical antipsychotic (olanzapine, quetiapine, risperidone, aripiprazole), with benzodiazepines short-term for agitation;

antidepressants alone can trigger mania in bipolar disorder.

Maintenance: lithium (which also lowers suicide risk), valproate, lamotrigine (for bipolar depression) and quetiapine.

Lithium monitoring:

  • levels 12 hours after a dose;
  • renal and thyroid function and calcium every 6 to 12 months;

teach patients to avoid dehydration and NSAIDs .

Anxiety disorders (generalized anxiety, panic, social anxiety):

  • SSRIs or SNRIs plus CBT as first-line;
  • buspirone (a 5-HT1A partial agonist, not addictive, slow onset) for generalized anxiety;
  • benzodiazepines only short-term, because of dependence, falls and cognitive effects in older adults;

propranolol for performance anxiety.

Insomnia:

sleep hygiene and CBT for insomnia first;

short courses of hypnotics if needed: Z-drugs (zolpidem), low-dose benzodiazepines, or melatonin in some patients;

avoid long-term sedatives, especially in older adults;

treat underlying depression, pain and sleep apnea.

Psychiatric emergencies

Acute agitation or aggression:

de-escalation first;

rapid tranquilization if needed, with IM haloperidol with lorazepam (or midazolam), or IM olanzapine (not with parenteral benzodiazepines);

monitor airway, vital signs and ECG (QT);

look for medical causes: hypoglycemia, hypoxia, delirium, intoxication or withdrawal, head injury.

Acute dystonia after antipsychotics: IM or IV diphenhydramine or benztropine .

Alcohol withdrawal:

symptoms begin 6 to 24 hours after the last drink, with seizures at 12 to 48 hours and delirium tremens at 48 to 96 hours;

treat with benzodiazepines (diazepam, chlordiazepoxide, or lorazepam in liver disease), using symptom-triggered dosing (CIWA-Ar) ;

give thiamine before glucose ;

correct electrolytes and magnesium.

Opioid withdrawal: uncomfortable but rarely fatal. Methadone or buprenorphine maintenance treats opioid use disorder.

Lithium toxicity: stop lithium, give IV fluids (normal saline), and use hemodialysis for severe toxicity (high levels with neurologic signs or renal failure).

Suicide risk: prescribe limited quantities of drugs that are dangerous in overdose (tricyclics, lithium). Involve the family and follow up closely.